Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Inder Anand

Showing results (31-40 of 110) with videos related to

Pageof 11
Sort By:
European Journal of Heart Failure|March 22, 2017
Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fractionTor Biering-Sørensen, Sanjiv J Shah, Inder Anand, et al.
The American Journal of Cardiology|February 22, 2005
Impact of nonfatal myocardial infarction on outcomes in patients with advanced heart failure and the effect of bucindolol therapyChristopher M O'Connor, Steven Gottlieb, Jamieson M Bourque, et al.
Circulation|October 18, 2012
Important differences in mode of death between men and women with heart failure who would qualify for a primary prevention implantable cardioverter-defibrillatorRobert W Rho, Kristen K Patton, Jeanne E Poole, et al.
Journal of the American College of Cardiology|December 20, 2005
Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trialPeter Carson, Inder Anand, Christopher O'Connor, et al.
American Heart Journal|October 12, 2010
Determination of hospitalization type by investigator case report form or adjudication committee in a large heart failure clinical trial (β-Blocker Evaluation of Survival Trial [BEST])Peter Carson, Mona Fiuzat, Christopher O'Connor, et al.
ESC Heart Failure|August 31, 2020
Patient-reported outcomes in heart failure with preserved vs. reduced ejection fraction: focus on physical independenceWeiting Huang, Tiew-Hwa Katherine Teng, Wan Ting Tay, et al.
ESC Heart Failure|October 23, 2017
Chronic obstructive pulmonary disease and β-blocker treatment in Asian patients with heart failureYoshiaki Kubota, Wan Ting Tay, Kuniya Asai, et al.
European Journal of Heart Failure|November 18, 2017
Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trialSenthil Selvaraj, Brian Claggett, Sanjiv J Shah, et al.
Circulation|June 23, 2017
Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist)Sheila M Hegde, Brian Claggett, Amil M Shah, et al.
Journal of Cardiac Failure|February 4, 2012
Cardiac resynchronization therapy in the real world: comparison with the COMPANION studyAlan J Bank, Kevin V Burns, Ryan M Gage, et al.
Pageof 11

Showing results (31-40 of 110) with videos related to

Sort By:
Pageof 11
European Journal of Heart Failure|March 22, 2017
Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fractionTor Biering-Sørensen, Sanjiv J Shah, Inder Anand, et al.
The American Journal of Cardiology|February 22, 2005
Impact of nonfatal myocardial infarction on outcomes in patients with advanced heart failure and the effect of bucindolol therapyChristopher M O'Connor, Steven Gottlieb, Jamieson M Bourque, et al.
Circulation|October 18, 2012
Important differences in mode of death between men and women with heart failure who would qualify for a primary prevention implantable cardioverter-defibrillatorRobert W Rho, Kristen K Patton, Jeanne E Poole, et al.
Journal of the American College of Cardiology|December 20, 2005
Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trialPeter Carson, Inder Anand, Christopher O'Connor, et al.
American Heart Journal|October 12, 2010
Determination of hospitalization type by investigator case report form or adjudication committee in a large heart failure clinical trial (β-Blocker Evaluation of Survival Trial [BEST])Peter Carson, Mona Fiuzat, Christopher O'Connor, et al.
ESC Heart Failure|August 31, 2020
Patient-reported outcomes in heart failure with preserved vs. reduced ejection fraction: focus on physical independenceWeiting Huang, Tiew-Hwa Katherine Teng, Wan Ting Tay, et al.
ESC Heart Failure|October 23, 2017
Chronic obstructive pulmonary disease and β-blocker treatment in Asian patients with heart failureYoshiaki Kubota, Wan Ting Tay, Kuniya Asai, et al.
European Journal of Heart Failure|November 18, 2017
Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trialSenthil Selvaraj, Brian Claggett, Sanjiv J Shah, et al.
Circulation|June 23, 2017
Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist)Sheila M Hegde, Brian Claggett, Amil M Shah, et al.
Journal of Cardiac Failure|February 4, 2012
Cardiac resynchronization therapy in the real world: comparison with the COMPANION studyAlan J Bank, Kevin V Burns, Ryan M Gage, et al.
Pageof 11